{
    "brief_title": "Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Solid Tumor Malignancies",
    "phase": "Phase 1; Phase 2",
    "drugs": "['BT8009', 'Pembrolizumab']",
    "drugs_list": [
        "BT8009",
        "Pembrolizumab"
    ],
    "diseases": "['Advanced Solid Tumor', 'Urinary Bladder Neoplasm', 'Triple Negative Breast Neoplasms', 'Carcinoma, Non-Small-Cell Lung', 'Ovarian Neoplasm']",
    "diseases_list": [
        "Advanced Solid Tumor",
        "Urinary Bladder Neoplasm",
        "Triple Negative Breast Neoplasms",
        "Carcinoma",
        "Non-Small-Cell Lung",
        "Ovarian Neoplasm"
    ],
    "enrollment": "329.0",
    "inclusion_criteria": "Key inclusion criteria \n\n Life expectancy \u226512 weeks. \n\n Patients must have measurable disease per RECIST 1.1. \n\n Part A-1 cohorts: \n\n Must have exhausted all standard treatment options, including appropriate targeted therapies; or patients for which no standard therapy is considered appropriate \n\n Patients with advanced, histologically confirmed urothelial (transitional cell) carcinoma that recurred after or has been refractory to prior therapy (fresh tumor biopsy or an archived sample must be submitted); or \n\n Patients with advanced, histologically confirmed pancreatic, breast, non-small-cell lung cancer (NSCLC), gastric, esophageal, head and neck, or ovarian tumors that recurred after or has been refractory to prior therapy (fresh tumor biopsy or an archived sample testing for Nectin-4 expression). \n\n Part A-2: \n\n Must have exhausted all standard treatment options, including appropriate targeted therapies; or patients for which no standard therapy is considered appropriate \n\n Patients with advanced, histologically confirmed urothelial (transitional cell) carcinoma that recurred after or has been refractory to prior therapy \n\n Cohort B-1: Histologically documented urothelial carcinoma, previously treated with enfortumab vedotin (EV). Patients with resectable, locally advanced urothelial carcinoma are ineligible. Must have had progression or recurrence of urothelial cancer during or following receipt of most recent therapy. \n\n Cohort B-2 and B-3: Histologically documented urothelial carcinoma, not previously treated with enfortumab vedotin (EV). Patients with resectable, locally advanced urothelial carcinoma are ineligible. Must have had progression or recurrence of urothelial cancer during or following receipt of most recent therapy. \n\n Cohort B-4: Histologically confirmed non-mucinous epithelial ovarian, fallopian tube, or primary peritoneal cancer that is Stage III or IV according to the International Federation of Gynecology and Obstetrics (FIGO) or tumor, node and metastasis staging criteria that recurred after or has been refractory to prior therapy. \n\n Cohort B-5: Breast cancers that have been confirmed negative for estrogen receptor (ER) and progesterone receptor (PR) and negative for human epidermal growth factor receptor 2 (HER2) (i.e., triple-negative) that have recurred after or has been refractory to prior therapy. \n\n Cohort B-6: Histologically confirmed non-small cell lung cancer (NSCLC) with no actionable mutations, such as Epidermal Growth Factor Receptor (EGFR) mutation, anaplastic lymphoma kinase (ALK) fusion oncogene, or ROS1 that recurred after or has been refractory to prior therapy. \n\n Cohort B-7: Locally advanced or metastatic, histologically confirmed urothelial (transitional cell) carcinoma, ineligible for cisplatin, no prior systemic anticancer treatment for advanced urothelial carcinoma. \n\n Cohort C renal insufficiency cohort: Patients with histologically documented urothelial carcinoma that recurred after or has been refractory to prior therapy. \n\n Key ",
    "exclusion_criteria": " (all patients): \n\n Clinically relevant troponin elevation \n\n Uncontrolled diabetes \n\n Uncontrolled, symptomatic brain metastases \n\n Patients with uncontrolled hypertension \n\n History of another malignancy within 3 years before first dose of BT8009 or residual disease from a previously diagnosed malignancy (with some exceptions). \n\n Active systemic infection requiring therapy, or fever within the last 14 days prior to first dose of BT8009. \n\n Prior Stevens-Johnson syndrome/toxic epidermal necrolysis on any MMAE-conjugated drug \n\n Parts A-2 and B-7 Pembrolizumab Combination Cohorts: \n\n Prior organ transplant (including allogeneic) \n\n Diagnosis of clinically relevant immunodeficiency \n\n History of interstitial lung disease \n\n Parts B-2 and B-3: Prior treatment with enfortumab vedotin \n\n Other protocol-defined Inclusion/",
    "brief_summary": "This clinical trial is evaluating a drug called BT8009 alone and in combination with pembrolizumab in participants with advanced solid tumors associated with Nectin-4 expression or in participants with advanced solid tumor malignancies having renal insufficiency.~The main goals of this study are to:~Find the recommended dose of BT8009 that can be given safely to participants alone and in combination with pembrolizumab~Learn more about the side effects and effectiveness of BT8009 alone and in combination with pembrolizumab~Learn more about BT8009 alone and in combination with pembrolizumab~Learn more about BT8009 alone in patients with renal insufficiency",
    "NCT_ID": "NCT04561362"
}